Table 3.
Baseline characteristics of patients receiving frontline venetoclax-based low-intensity therapy
| Total n = 976 n (%) |
NHW n = 870 n (%) |
NHB n = 61 n (%) |
Hispanic n = 45 n (%) |
|
|---|---|---|---|---|
| Median age, y | 75.5 | 76.0 | 75.0 | 76.0 |
| Sex, male | 576 (59) | 531 (61) | 22 (36) | 23 (51) |
| ELN2017∗ | n = 817 | n = 733 | n = 48 | n = 36 |
| Favorable | 71 (9) | 62 (9) | 5 (10) | 4 (11) |
| Intermediate | 320 (39) | 283 (39) | 25 (52) | 12 (33) |
| Adverse | 426 (52) | 388 (53) | 18 (38) | 20 (56) |
| Venetoclax-favorable mutations∗ | n = 794 | n = 714 | n = 49 | n = 31 |
| NPM1 | 78 (10) | 71 (10) | 3 (6) | 4 (13) |
| IDH1 | 70 (9) | 64 (9) | 6 (12) | 0 (0) |
| IDH2 | 100 (13) | 85 (12) | 8 (16) | 7 (23) |
| Venetoclax-unfavorable mutations∗ | n = 794 | n = 714 | n = 49 | n = 31 |
| TP53 | 140 (18) | 127 (18) | 8 (16) | 5 (16) |
| KRAS | 27 (3) | 26 (4) | 1 (2) | 0 (0) |
| NRAS | 56 (7) | 48 (7) | 5 (10) | 3 (10) |
| FLT3-ITD | 65 (8) | 59 (8) | 3 (6) | 3 (10) |
| Others, DNMT3A | 121 (15) | 102 (14) | 14 (29) | 5 (16) |
∗
Among patients whose information was available.